ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)

Liu, Si-Yang; Chen, Qixun; Zhou, Chengzhi; Zhang, Huizhong; Li, Wen; Chen, Jianhua; Hu, Jian; Wu, Lin; Chen, Qunqing; Dai, Qiangsheng; Shan, Jian-Zhen; Xu, Fei; Liu, Si-Yang Maggie*; Wu, Yi-Long*广东省人民医院; 广州医学院; 南昌大学; 南方医科大学; 浙江大学; 中山大学; 中国科学院研究生院; 1
Cancer Immunology, Immunotherapy2023-7DOI: 10.1007/s00262-023-03412-8
3被引9阅读
引用收藏
分享

摘要

BackgroundCamrelizumab has shown encouraging efficacy in advanced non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However, evidence of neoadjuvant camrelizumab for NSCLC remains lacking.MethodsPatients with NSCLC treated with neoadjuvant camrelizumab-based therapy followed by surgery between December 2020 and September 2021 were retrospectively reviewed. Demographic and clinical data, details of neoadjuvant therapy and surgical information were retrieved.ResultsIn this multicenter retrospective real-world study, 96 patients were included. Ninety-five patients (99.0%) received neoadjuvant camrelizumab combined with platinum-based chemotherapy, with a median of 2 cycles (range 1-6). The median interval from the last dose to surgery was 33 days (range 13-102 days). Seventy patients (72.9%) underwent minimally invasive surgery. Lobectomy was the most frequent surgical procedure (94 [97.9%]). The median estimated intraoperative blood loss was 100 mL (range 5-1200 mL), and the median operative time was 3.0 h (range 1.5-6.5 h). The R0 resection rate was 93.8%. Twenty-one patients (21.9%) experienced postoperative complications, with the most common being cough and pain (both 6 [6.3%]). The overall response rate was 77.1% (95% CI 67.4-85.0%), and the disease control rate was 93.8% (95% CI 86.9-97.7%). Twenty-six patients (27.1%, 95% CI 18.5-37.1%) had pathological complete response. Neoadjuvant treatment-related adverse events of grade >= 3 were reported in seven patients (7.3%), with the most frequent being abnormal liver enzymes (two [2.1%]). No treatment-related deaths were reported.ConclusionThe real-world data indicated that camrelizumab-based therapy had promising efficacy for NSCLC in the neoadjuvant setting, with manageable toxicities. Prospective studies investigating neoadjuvant camrelizumab are warranted.

学科与关键词

关键词
Non-small cell lung cancerNeoadjuvantCamrelizumabImmune checkpoint inhibitorReal-world study
相关
加载中…
  • Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)
    Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
  • Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
    Xu, C.; Chen, Q.; Zhou, C.; Wu, L.; Li, W.; Zhang, H.; Li, Y.; Xu, F.; Xiong, J.; Wang, Q.; Zhang, H.; Jiang, Y.; Yin, H.; Wu, Q.; Dai, Q.; Hu, J.; Chen, J.; Zhang, J.; Wu, G.; Wu, Y-L.ESMO Immuno-Oncology Congres, ELECTR NETWORK, 2021-12-08 To 2021-12-11.被引 2
  • Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
    Liu, Si-Yang; Dong, Song; Yang, Xue-Ning; Liao, Ri-Qiang; Jiang, Ben-Yuan; Wang, Qun; Ben, Xiao-Song; Qiao, Gui-Bin; Lin, Jun-Tao; Yan, Hong-Hong; Yan, Li-Xu; Nie, Qiang; Tu, Hai-Yan; Wang, Bin-Chao; Yang, Jin-Ji; Zhou, Qing; Li, Hong-Rui; Liu, Ke; Wu, Wendy; Liu, Si-Yang Maggie; Zhong, Wen-Zhao*; Wu, Yi-Long*Signal Transduction and Targeted Therapy, 2023, 8(1): 442.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Immunology, Immunotherapy
发表日期
2023-07
卷期
第 72 卷, 第 7 期
页码
2257-2265
DOI
10.1007/s00262-023-03412-8
语言
ENGLISH
成果收录
SCIE
资助标注
Chinese Thoracic Oncology Group (CTONG)

作者

  • L

    Liu, Si-Yang (第一作者)

  • C

    Chen, Qixun

    univ chinese acad sci

查看全部 14 位作者收起作者
  • Z

    Zhou, Chengzhi

    1 · guangzhou med univ

  • Z

    Zhang, Huizhong

    sun yat sen univ

  • L

    Li, Wen

    2 · zhejiang univ

  • C

    Chen, Jianhua

    hunan canc hosp

  • H

    Hu, Jian

    1 · zhejiang univ

  • W

    Wu, Lin

    2 · hunan canc hosp

  • C

    Chen, Qunqing

    southern med univ

  • D

    Dai, Qiangsheng

    1 · sun yat sen univ

  • S

    Shan, Jian-Zhen

    2 · zhejiang univ

  • X

    Xu, Fei

    nanchang univ

  • L

    Liu, Si-Yang Maggie (通讯)

    1

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417